Drug intelligence / Profile preview

IAG regimen

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous, Inhalation

Overview

IAG is a chemotherapy regimen primarily investigated for the treatment of myelodysplastic syndrome (MDS) and MDS-transformed acute myeloid leukemia (AML). The regimen typically comprises Idarubicin, an anthracycline topoisomerase II inhibitor; Cytarabine (Ara-C), an antimetabolite that interferes with DNA synthesis; and Granulocyte-colony stimulating factor (G-CSF), a hematopoietic growth factor that stimulates the production of granulocytes. This combination aims to induce remission by targeting rapidly dividing cancer cells while supporting bone marrow recovery.

Targets

CSF3R (Granulocyte colony-stimulating factor receptor)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on IAG regimen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IAG regimen.

Explore the full profile